Set up in 2002, La Merie Publishing is an authoritative supplier of the cutting-edge information on the biopharmaceutical industry, with a special focus on the research and development pipeline and covering issues related to biologics, including peptides, antibodies, DNA, RNA, proteins and cell therapy.
The company’s service portfolio is represented by various formats and price levels, and includes Brief Reports, Full Reports and Competitor Analysis Reports. Competitor Analysis Reports present no frills, but accurate data on the pipeline of research and development projects for diseases, targets, companies and technologies. The data are fully referenced and delivered in a tabular format. Brief Reports covering Target Pipelines contain all-round assessments of both business and scientific perspectives of new targets. Full Reports present deep analyses of product portfolios, competitive landscape, R&D pipelines and discussions of the pipeline perspectives.
Publications found:
225
Sort by:
Report Package: “Drug the Undruggable” Technologies
US$ 4,700.00
Report Package: “Drug the Undruggable” Technologies This report package includes four full reports for the price of two: Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a land...
May 2020
Competitor Analysis: KRAS Inhibitors
US$ 280.00
Competitor Analysis: KRAS Inhibitors This Competitive Intelligence report about KRAS Inhibitors evaluates the landscape of investigational small molecules, antibodies, cell therapeutics and vaccines t...
October 2019
35 pages
Competitor Analysis: RORgamma Antagonists and Agonists
US$ 280.00
Competitor Analysis: RORgamma Antagonists and Agonists This Competitive Intelligence report about RORgamma Antagonists and Agonists evaluates the landscape of investigational small molecules targeting...
September 2019
28 pages
Competitor Analysis: TGF-beta/Receptor Inhibitors
US$ 340.00
Competitor Analysis: TGF-beta/Receptor Inhibitors This Competitive Intelligence report about TGF-beta/Receptor Inhibitors evaluates the landscape of investigational new molecular entities targeting tr...
September 2019
59 pages
Report Package: Bispecific Antibodies
US$ 2,840.00
Report Package: Bispecific Antibodies This report package includes the full report T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis and the ...
June 2019
Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018
US$ 590.00
Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018 This Competitive Intelligence report analyzes the competitive field of CD40, GITR, OX40, 4-1BB, CD27, ICOS ...
July 2018
78 pages
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, adenosine pathway & STING 2018
US$ 940.00
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway ... . In addition, the report lists company-specific R&D pipelines of modulators of the tumor microenvironment. Competitor projects are listed in a tabular format providing information on: Drug ...
July 2018
204 pages
Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators
US$ 1,690.00
Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators This product consists of four reports in pdf ... include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of ...
July 2018
455 pages
Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018
US$ 710.00
Competitor Analysis: PD-1 and PD-L1 ... specific R&D pipelines of PD-1 and PD-L1 checkpoint inhibitors. Competitor projects are listed in a tabular format providing information ... to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information ...
June 2018
89 pages
Competitor Analysis: PRAME-Targeted Immunotherapy
US$ 177.00
Competitor Analysis: PRAME-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of PRAME-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data. PRAME (preferentially ...
June 2018
23 pages
Competitor Analysis: WT1-Targeted Immunotherapy
US$ 354.00
Competitor Analysis: WT1-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of WT1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...
June 2018
52 pages
Competitor Analysis: hTERT-Targeted Immunotherapy
US$ 177.00
Competitor Analysis: hTERT-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of hTERT-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...
June 2018
20 pages
Competitor Analysis: NY-ESO-1-Targeted Immunotherapy
US$ 472.00
Competitor Analysis: NY-ESO-1-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of NY-ESO-1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...
June 2018
72 pages
Competitor Analysis: MAGE-A-Targeted Immunotherapy
US$ 177.00
Competitor Analysis: MAGE-A-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of MAGE-A-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...
June 2018
28 pages
Competitor Analysis: Survivin-Targeted Immunotherapy
US$ 236.00
Competitor Analysis: Survivin-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of Survivin-Targeted Immunotherapies as of May 2018 in a tabulated format with structured listings of industry-relevant ...
May 2018
28 pages
Report Package: TCR-Based Antibody and T-Cell Immunotherapy
US$ 3,505.00
T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of ... or T-cell redirecting bispecific antibodies. This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy ...
April 2018
Competitor Analysis: Kallikrein Inhibitors 2017
US$ 170.00
Competitor Analysis: Kallikrein Inhibitors & Bradykinin Receptor Antagonists The present Competitive Intelligence report aboutKallikrein Inhibitors & Bradykinin Receptor Antagonists provides a competitor evaluation in the field of marketed and novel ...
April 2017
17 pages
The Oncolytic Virus Landscape 2017: an Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities
US$ 2,400.00
The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities The field of oncolytic viruses was quite dormant in the first decade of the 2000s ... „The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities“ as of January 2017 brings you up-to-date regarding key players, key technologies, Oncolytic Virus projects ...
January 2017
225 pages
Competitor Analysis: CSF-1R Antagonists for Modulation of the Tumor Microenvironment
US$ 367.00
Competitor Analysis: CSF-1R Antagonists for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of novel colony stimulating receptor 1 (CSF-1R) antagonists for modulation of the immunosuppressive tumor microenvironment as of December 2016. The Competitor Analysis includes antibody-based antagonists of CSF-1R as well as small molecule inhibitors of CSF-1R tyrosine ...
December 2016
19 pages
Competitor Analysis: CXCR4 Antagonists for Modulation of the Tumor Microenvironment
US$ 367.00
Competitor Analysis: CXCR4 Antagonists for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of novel antagonists of the C-X-C chemokine receptor type 4 (CXCR4) and ... 2016. The Competitor Analysis includes antagonists of CXCR4 based on small molecules, peptides and antibodies as well as inhibitors of CXCL12, the ligand for CXCR4. Included are molecules ...
December 2016
20 pages
Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment
US$ 367.00
Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of specific IDO and TDO inhibitors as well as dual ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...
December 2016
38 pages
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology
US$ 2,310.00
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology This product consists of four reports in pdf ... Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPα, Adenosine, STING & Others Targets of Immunomodulators are inhibitory as well as stimulatory immune ...
December 2016
319 pages
Competitor Analysis: TGF-? Inhibitors for Modulation of the Tumor Microenvironment
US$ 367.00
Competitor Analysis: TGF-β Inhibitors for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of specific TGF-beta inhibitors as well as TGF-beta receptor antagonists ... 2016. The Competitor Analysis includes antibody-based inhibitors of transforming growth factor beta (TGF-beta) or antagonists of TGF-beta receptors as well as small molecule inhibitors of TGF-beta receptor ...
December 2016
22 pages
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?/R, CXCR4, CSF-1R, CD47-SIRP?, Adenosine, STING & Others
US$ 1,283.00
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPα, Adenosine, STING & Others This Competitive Intelligence report about Tumor Microenvironment Modulation via IDO, TGF ... active projects in research and development of modulators of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of Tumor Microenvironment Modulators. Competitor projects are listed in a tabular format ...
December 2016
117 pages
Report Package: Hot targets for empowered antibody and cell therapy technologies
US$ 2,090.00
... Package: Hot targets for empowered antibody and cell therapy technologies This package contains three reports analyzing BCMA, CD123 and CD22 as versatile and hot targets ... package of the three reports provides a 40% discount on the regular prices: B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities CD123: a paradigmatic target ...
December 2016
202 pages
Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company
US$ 880.00
Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates and describes the competitive landscape of antibody-drug conjugates ... -specific R&D pipelines of ADCs. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target/Mechanism of Action, Class of Compound (antibody, linker, payload ...
December 2016
288 pages
R&D Drug Pipeline Database: 1-Year Subscription
US$ 6,600.00
... Drug Pipeline Database: 1-Year Subscription Subscription to La Merie Publishing's proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project ... a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase. Benefits from the R&D Drug Pipeline Database ...
November 2016
Flat-Rate Access to R&D Database & Reports from La Merie Publishing
US$ 8,470.00
Unbenanntes Dokument Flat-Rate Access to R&D Database & Reports from La Merie Publishing R&D Drug Pipeline Database: 1-Year Subscription Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-year ... . Internet access is the only prerequisite for this service. Upon purchse of the Flat-Rate Access to R&D Database & Reports from La Merie Publishing, credentials to access the database and a dedicated ...
November 2016
Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates
US$ 225.00
Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates This pdf ... Pipeline: Anti-CD22 Immunotherapeutics CD-22Targeted Immunotherapeutics include: Naked Antibodies & Combinations Radioimmunotherapeutics Immunotoxins Antibody-Drug Conjugates Autologous CAR T-Cells Information about the anti-CD22 Immunotherapeutics pipeline ...
November 2016
27 pages
BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies
US$ 225.00
BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies This pdf report contains information about Bispecific Antibodies released during the month of October 2016 ... Tracker for Bispecific Antibodies. Featured presentations of October 2016 include the pipeline of B-Cell Maturation Antigen (BCMA)-targeted immunotherapeutics, the profile of German technology company Pieris ...
November 2016
21 pages
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
US$ 784.00
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment ... , CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the extracellular environment, features that make it an attractive antigen for ...
November 2016
80 pages